Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
1e5 of Mouse Anti-CD8 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 647-Labeled Human CD8 alpha Protein, His Tag (Cat. No. CDA-HA2H5) and negative control protein respectively, AF647 signal was used to evaluate the binding activity (QC tested).
1e5 of Mouse Anti-CD8 antibody coupled beads (5.5 μm) were stained with different concentration of Alexa Fluor 647-Labeled Human CD8 alpha Protein, His Tag (Cat. No. CDA-HA2H5) and negative control protein respectively, AF647 signal was used to evaluate the binding activity (QC tested).
Immobilized Biotinylated Cynomolgus CD8 alpha Protein, His,Avitag (Cat. No. CDA-C82E7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-CD8 alpha Antibody, Human IgG1 with a linear range of 0.06-1 ng/mL (QC tested).
The purity of Biotinylated Cynomolgus CD8 alpha Protein, His,Avitag (Cat. No. CDA-C82E7) is more than 90% and the molecular weight of this protein is around 50-60 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Multiple Sclerosis; Lymphoma; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
| CD8+ memory T cell therapy (Stanford University) | Phase 2 Clinical | Stanford University | Leukemia; Leukemia, Myelogenous, Chronic; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details | |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Skin Melanoma; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Carcinoma, Non-Small-Cell Lung | Details |
| VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Esophageal Neoplasms; Stomach Neoplasms; Colorectal Neoplasms; Melanoma; Neoplasm Metastasis | Details |
| EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | Details | |
| ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasms; Neoplasm Metastasis | Details |
| NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma, Synovial; Sarcoma | Details | |
| MTX-101 (Mozart Therapeutics) | MTX-101 (Mozart Therapeutics) | Phase 1 Clinical | Mozart Therapeutics Inc | Diabetes Mellitus, Type 1; Autoimmune Diseases; Celiac Disease | Details |
| Fluorine-18 (18F) CD8-targeted imaging radiopharmaceutical(Ge Healthcare) | GEH200521 (18F); GEH-200521 | Phase 1 Clinical | Ge Healthcare | Solid tumours; Neoplasms | Details |
| Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Stomach Neoplasms; Esophageal Neoplasms | Details | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| AGX-148 | AGX-148; AGX148 | Phase 1 Clinical | AgonOx Inc | Squamous Cell Carcinoma of Head and Neck; Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Lung Neoplasms; Melanoma | Details |
| SNA-006 | 68Ga-NODAGA-SNA006; SNA-006; 68-Ga-NODAGA-SNA-006 | Phase 1 Clinical | Smartnuclide Biopharma | Solid tumours | Details |
| AGX-392 | AGX-392 | AgonOx Inc | Details |
This web search service is supported by Google Inc.
A-Z
